Andrew Murphy, Ph.D., brings more than 18 years of biotechnology experience spanning gene therapy research, translational development and regulatory advancement. Prior to joining Opus Genetics, Dr. Murphy served as Senior Vice President of Research and Early Development at Kriya Therapeutics, where he led AAV vector design, research, genomics and data science activities, advancing gene therapy candidates across ophthalmology, metabolic, neurological and rare diseases.
Throughout his career, he has supported seven therapeutic programs through Phase 1 IND or CTA submissions, including five during his tenure at Kriya Therapeutics. Previously, Dr. Murphy founded Kitty Hawk Biosciences, a gene therapy consultancy focused on AAV vector characterization and potency assay development, and held scientific leadership positions at KBI Biopharma, Duke University Medical Center, ProteoVec and Liquidia Technologies. He holds a Ph.D. in Chemistry from Stanford University and a B.A. in Chemistry from Oberlin College.
